Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022
August 03 2022 - 7:00AM
Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company
dedicated to improving the delivery of healthcare to patients,
today announced that it will host a live conference call and
webcast at 8:00 a.m. EDT on Monday, August 15, 2022 to report its
financial results for the first quarter ended June 30, 2022 and
provide a corporate update.
To access the conference call by phone, please
register online using this registration link. A webcast of the call
will also be available under “Events & Presentations” in the
Investors section of the Roivant website at
https://investor.roivant.com/news-events/events. The archived
webcast will be available on Roivant’s website after the conference
call.
In addition, Roivant will host a virtual investor
day on Wednesday, September 28, at 11:00 a.m. EDT in order to
provide updates across Roivant and the Vants. Participants can
register to attend at
https://hopin.com/events/roivantinvestorday2022/registration.
About Roivant SciencesRoivant's
mission is to improve the delivery of healthcare to patients by
treating every inefficiency as an opportunity. Roivant develops
transformative medicines faster by building technologies and
developing talent in creative ways, leveraging the Roivant platform
to launch 'Vants' – nimble and focused biopharmaceutical and health
technology companies. For more information, please visit
www.roivant.com.
Roivant Sciences Forward-Looking
Statements
This press release contains forward-looking
statements. Statements in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), which are
usually identified by the use of words such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intends,"
"may," "might," "plan," "possible," "potential," "predict,"
"project," "should," "would" and variations of such words or
similar expressions. The words may identify forward-looking
statements, but the absence of these words does not mean that a
statement is not forward-looking. We intend these forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not
limited to, statements regarding our or our management team's
expectations, hopes, beliefs, intentions or strategies regarding
the future, and statements that are not historical facts, including
statements about the clinical and therapeutic potential of our
product candidates, the availability and success of topline results
from our ongoing clinical trials, any commercial potential of our
product candidates and any pending or potential litigation,
including but not limited to our expectations regarding the outcome
of any such litigation and costs and expenses associated with such
litigation. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking statements. All product candidates referenced in
this press release are investigational and subject to health
authority approval.
Although we believe that our plans, intentions,
expectations and strategies as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a number of risks, uncertainties and
assumptions, including, but not limited to, those risks set forth
in the Risk Factors section of our filings with the U.S. Securities
and Exchange Commission. Moreover, we operate in a very competitive
and rapidly changing environment in which new risks emerge from
time to time. These forward-looking statements are based upon the
current expectations and beliefs of our management as of the date
of this press release, and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
required by applicable law, we assume no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts:
InvestorsRoivant Investor
Relationsir@roivant.com
MediaPaul Davispaul.davis@roivant.com
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Dec 2024 to Jan 2025
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Jan 2024 to Jan 2025